Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Chronic lymphocytic leukemia diagnostics guideline small lymphocytic lymphoma treatment

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 24 6 2022
medline: 12 10 2022
entrez: 23 6 2022
Statut: ppublish

Résumé

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.

Identifiants

pubmed: 35737364
doi: 10.1080/10428194.2022.2084731
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2276-2289

Auteurs

Doreen G Te Raa (DGT)

Department of Internal Medicine, Gelderse Vallei, Ede, the Netherlands.

Lina van der Straten (L)

Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, the Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Laboratory Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.

Michel van Gelder (M)

Department of Hematology, Maastricht UMC, the Netherlands Maastricht.

Sabina Kersting (S)

Department of Internal Medicine, HAGA hospital, Den Haag, the Netherlands.

Mark-David Levin (MD)

Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, the Netherlands.

Rogier Mous (R)

Department of Hematology, UMC Utrecht, the Netherlands Utrecht.

Hanneke M van der Straaten (HM)

Department of Internal Medicine, St Jansdal hospital, Harderwijk, the Netherlands.

Marten R Nijziel (MR)

Department of Internal Medicine, Catharina hospital, Eindhoven, the Netherlands.

Ellen van der Spek (E)

Department of Internal Medicine, Rijnstate, Arnhem, the Netherlands.

Eduardus F M Posthuma (EFM)

Department of Internal Medicine, Reinier de Graaf hospital, Delft, the Netherlands.
Department of Hematology, Leiden Univerisity Medical Center, Leiden, the Netherlands.

Hein P J Visser (HPJ)

Department of Internal Medicine, Noordwest ziekenhuisgroep, Alkmaar, the Netherlands.

Marjolein van der Klift (M)

Department of Internal Medicine Amphia hospital, Breda, the Netherlands.

Koen de Heer (K)

Department of Internal Medicine, Flevo hospital, Almere, the Netherlands.

Mar Bellido (M)

Department of Hematology, Groningen University Medical Center, University of Groningen, Groningen, the Netherlands.

Jeanette K Doorduijn (JK)

Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Anke H W Bruns (AHW)

Department of Hematology, UMC Utrecht, the Netherlands Utrecht.

Reinier A P Raijmakers (RAP)

Department of Hematology, UMC Utrecht, the Netherlands Utrecht.

Arnon P Kater (AP)

Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH